AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]
Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]
Anaptys Announces Participation in December Investor Conferences
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.